Quality of life and tolerability of B-cell directed therapy of multiple sclerosis with ofatumumab in a patient-centered real-world observational study.
Anti-CD20 monoclonal antibody
B-cell depletion
Multiple sclerosis
Ofatumumab
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
22 Jul 2024
22 Jul 2024
Historique:
received:
27
05
2024
accepted:
12
07
2024
revised:
10
07
2024
medline:
23
7
2024
pubmed:
23
7
2024
entrez:
22
7
2024
Statut:
aheadofprint
Résumé
Ofatumumab (Kesimpta In this prospective observational real-world study, we report follow up data of 81 patients. We evaluated sociodemographic data, disease duration, duration and side effects of ofatumumab use, expanded disability status scale (EDSS), Beck Depression Inventory II (BDI-II), Short-Form 36 (SF-36), Fatigue Scale of Motor and Cognitive Functions (FSMC), and modified Multiple Sclerosis Functional Composite Test (MSFC). In addition, we asked for subjective treatment outcomes, such as impact on quality of life, walking distance, concentration, mood, medication adherence, fatigue and the subjective course of MS on a numerical rating scale (1 = very negative; 5 = very positive). Furthermore, treatment discontinuations were recorded. The average duration of ofatumumab treatment was 10 months. In comparison to previous published data of our cohort, patients reported a significant increase in headache (10% up to 26%, p = 0.004) and limb pain (5% up to 26%, p < 0.001) as persistent side effects after the injections. More patients reported a very positive effect (p < 0.0001) on quality of life. 4 confirmed relapses occurred but no EDSS worsening, and no treatment discontinuations were documented during the observation period. As previously described, our prospective study indicates that patients have a good tolerability of ofatumumab, precisely because of the mild and few side effects at the first administration. However, the longer the observation period, the more headaches and limb pain occurred after the injections. Despite this, patients' subjective quality of life improved. There were no discontinuations during the follow-up period, with the limitation of a high loss to follow-up.
Identifiants
pubmed: 39039273
doi: 10.1007/s00415-024-12581-0
pii: 10.1007/s00415-024-12581-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Lublin FD, Häring DA, Ganjgahi H, Ocampo A, Hatami F, Čuklina J, Aarden P, Dahlke F, Arnold DL, Wiendl H, Chitnis T, Nichols TE et al (2022) How patients with multiple sclerosis acquire disability. Brain 145:3147–3161
doi: 10.1093/brain/awac016
pubmed: 35104840
pmcid: 9536294
Kavaliunas A, Manouchehrinia A, Stawiarz L, Ramanujam R, Agholme J, Hedström AK, Beiki O, Glaser A, Hillert J (2017) Importance of early treatment initiation in the clinical course of multiple sclerosis. Mult Scler 23:1233–1240
doi: 10.1177/1352458516675039
pubmed: 27754943
Chalmer TA, Baggesen LM, Nørgaard M, Koch-Henriksen N, Magyari M, Sorensen PS (2018) Early versus later treatment start in multiple sclerosis: a register-based cohort study. Eur J Neurol 25:1262-e110
doi: 10.1111/ene.13692
pubmed: 29847005
He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, Sharmin S, Horakova D, Kubala Havrdova E, Spelman T, Izquierdo G, Eichau S et al (2020) Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol 19:307–316
doi: 10.1016/S1474-4422(20)30067-3
pubmed: 32199096
Delgado SR, Faissner S, Linker RA, Rammohan K (2024) Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment. J Neurol 271:1515–1535
doi: 10.1007/s00415-023-12007-3
pubmed: 37906325
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung H-P, Hemmer B, Lublin F, Rammohan KW et al (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376:209–220
doi: 10.1056/NEJMoa1606468
pubmed: 28002688
Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676–688
doi: 10.1056/NEJMoa0706383
pubmed: 18272891
Faissner S, Plemel JR, Gold R, Yong VW (2019) Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. Nat Rev Drug Discov 18:905–922
doi: 10.1038/s41573-019-0035-2
pubmed: 31399729
Bar-Or A, Wiendl H, Montalban X, Alvarez E, Davydovskaya M, Delgado SR, Evdoshenko EP, Giedraitiene N, Gross-Paju K, Haldre S, Herrman CE, Izquierdo G et al (2022) Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler 28:910–924
doi: 10.1177/13524585211044479
pubmed: 34605319
Spelman T, Magyari M, Piehl F, Svenningsson A, Rasmussen PV, Kant M, Sellebjerg F, Joensen H, Hillert J, Lycke J (2021) Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies. JAMA Neurol 78:1197–1204
doi: 10.1001/jamaneurol.2021.2738
pubmed: 34398221
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H et al (2020) Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med 383:546–557
doi: 10.1056/NEJMoa1917246
pubmed: 32757523
Klimas R, Karl A-S, Poser PL, Sgodzai M, Theile-Ochel S, Gisevius B, Faissner S, Nastos I, Gold R, Motte J (2023) Over one year of B-cell targeted therapy with Ofatumumab s.c.: first results of a prospective, patient-centered real-world observational study. Nervenarzt 94:923–933
doi: 10.1007/s00115-023-01470-y
pubmed: 37042954
pmcid: 10576000
Ellert U, Kurth B-M (2004) Methodische Betrachtungen zu den Summenscores des SF-36 anhand der erwachsenen bundesdeutschen Bevölkerung. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 47:1027–1032
doi: 10.1007/s00103-004-0933-1
pubmed: 15549195
Moons KGM, de Groot JAH, Bouwmeester W, Vergouwe Y, Mallett S, Altman DG, Reitsma JB, Collins GS (2014) Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. PLoS Med 11:e1001744
doi: 10.1371/journal.pmed.1001744
pubmed: 25314315
pmcid: 4196729
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS et al (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376:221–234
doi: 10.1056/NEJMoa1601277
pubmed: 28002679
Mohr DC, Boudewyn AC, Likosky W, Levine E, Goodkin DE (2001) Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med 23:125–132
doi: 10.1207/S15324796ABM2302_7
pubmed: 11394554
Bhan V, Clift F, Baharnoori M, Thomas K, Patel BP, Blanchette F, Adlard N, Vudumula U, Gudala K, Dutta N, Grima D, Mouallif S et al (2023) Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada. J Comp Eff Res 12:e220175
doi: 10.57264/cer-2022-0175
pubmed: 37606897
pmcid: 10690431
Gold R, Schmidt S, Deisenhammer F, Motte J, Richter N, Taipale K, Salmen HC, Bohland C, Schirduan K (2024) Real-world evidence and patient preference for subcutaneous versus intravenous natalizumab in the treatment of relapsing-remitting multiple sclerosis - initial results from the observational SISTER study. Ther Adv Neurol Disord 17:17562864241241382
doi: 10.1177/17562864241241382
pubmed: 38616781
pmcid: 11015759